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Female fertility can be aﬀected by diseases or dysfunctions of reproductive tract, neuroendocrine system, and immune system.
Reproductive autoimmune failure can be associated with overall activation of immune system or with immune system reactions
speciﬁcally directed against ovarian antigens. Majority of the antiovarian autoantibodies are directed against β-subunit of follicle
stimulating hormone (anti-FSH). This paper summarizes a current clinical classiﬁcation of female infertility in the context of
general activation of autoimmunity and antiovarian autoimmunity by describing serum anti-FSH. The presence of naturally
occurring anti-FSH in healthy women will be discussed. In addition, the putative impairment of ovarian folliculogenesis in case of
increased production of those antibodies in infertile women will be characterized.
1.Introduction
Infertility is a condition that aﬀects a couple and is deﬁned as
the lack of conception after an arbitrary period of 12 months
withoutusinganycontraception[1].Thesecouplescomprise
the infertile and the sterile members of the population,
for whom is no possibility of natural pregnancy, and the
remainder who are subfertile [2]. The latter inadvertently
includes normal fertile females who failed to conceive by
chance during the 12 or 13 opportunities a woman has
per year [1]. Infertility contributes a great proportion to
overallreproductiveillhealth,sincethereare ∼60–80million
infertile couples (∼15% of couples) around the world [2].
Minor fertility impairment is seen in both partners more
frequently than expected (>70% of infertile couples) [2].
Although infertility per se may not threaten physical health,
it may have a serious impact on the mental and social
well-being of couples and may result in detrimental social
consequences, such as divorce or ostracism [2]. In addition,
infertilitycontributestolowbirthrate,whichisamajorsocial
and national issue in developed countries.
Infertility represents an increasing medical problem. A
progressive decrease in fertility rate has been indicated since
1955 [1]. The decrease is associated with both medical and
nonmedical factors. Women’s age is the major determinant
of the average time required to conceive. The highest live
birth rates are in the age group of 25–30 years and declines
sharply after the age of 35 [3]. Also, the duration of infertility
contributes meaningful information to the estimation of
future fertility [4]. Chromosomal aberrations, monogenic
diseases, endocrine dysfunctions, sexually transmitted dis-
eases (STDs), and immune system dysfunctions are medical
situations, which can contribute both to male and female
infertility. Unfortunately, still in about 10%–20% of couples,
theinfertility causeremainsunknown[2].However,autoim-
mune mechanisms may be the case in those couples and
have been associated with premature ovarian failure (POF),
“subclinical” ovarian failure and with recurrent pregnancy
loss [1].
Nowadays, when the utilization of assisted reproduc-
tion technologies has improved the prospects of infertil-
ity treatment, still every second infertile couple seeks for2 Clinical and Developmental Immunology
medical advice [2]. First child following in vitro fertilization
(IVF) was born in 1978 [5]. Today, approximately 2.5%
of newborns account for IVF-treated couples in European
countries, which remains somewhat lower when compared
to Nordic countries [6]. Regardless of constant improvement
of pregnancy rate in IVF, the success rates are still around
30% per cycle [6]. Autoimmunity and the presence of
autoantibodies have been invoked as a possible mechanism
of IVF failure. There are contradicting data regarding
the importance of certain antibodies to damage directly
the preimplantation embryo, interfering with implantation
process or formation of placenta [7–11]. Consequently, the
overall activation of the immune system in female infertility
has been suggested [12].
For the purpose of improving infertility treatment, the
mechanisms of immune system associated with natural
reproduction as well as with infertility should be carefully
evaluated. This paper summarizes a current clinical classiﬁ-
cationoffemaleinfertilityinthecontextofgeneralactivation
of autoimmune processes and antiovarian autoimmunity by
describing serum antibodies to follicle stimulating hormone
(FSH).
2.Autoimmunity
Active tolerance mechanisms are required to prevent inﬂam-
matory responses to the many innocuous air-borne and food
antigens that are encountered at mucosal surfaces. However,
the most important aspect of tolerance is self-tolerance,
which prevents the body from mounting an immune
attackagainstitsowntissues—preventionfromautoimmune
reactions. Autoimmunity is associated with a dysbalance
of various components of the immune response and with
the development of autoantibodies directed against normal
host antigens. The susceptibility to autoimmune reactions
is regulated at several levels [13]. The proliferation of
mature T-lymphocytes in response to either self- or foreign
antigenic stimuli is aﬀected by the nature and strength of
antigenic peptide-MHC (major histocompatibility complex)
stimulation [13, 14]. Human leukocyte antigen (HLA)-class
II molecules inﬂuence the stability of the antigenic-peptide-
HLA complex in an allele-speciﬁc manner, aﬀecting the
inductionofcentraltolerance[13].Asrevealedbythestudies
on anti-insulin autoimmunity, the stimulation provided by
antigenicpeptide-MHCstimulationcouldalsobemodulated
by genetic variations of the insulin gene, inﬂuencing the
gene expression in the thymus [15, 16]. Tissue-speciﬁc
autoimmunity appears to be additionally dependent on
local factors, including infection-related tissue damage [13],
iatrogenicmanipulations[17],andthelevelofautoantigenin
periphery [18, 19]. Thus, the expansion of cells responding
to low-aﬃnity ligands (self-antigen) or anomalies in the
deletion of high-aﬃnity autoreactive T-cells can lead to
autoimmune reactions [14]. Once an autoimmune disease
has been developed, a wider range of autoimmune reactions
may progress, meaning that an individual may develop more
than one autoimmune disease [20].
3. ReproductiveAutoimmuneFailureinWomen
Female fertility is regulated by a series of highly coordi-
nated and synchronized interactions in the hypothalamic-
pituitary-ovarian axis. Therefore, female fertility can be
aﬀe c t e db yd i s e a s e so rd y s f u n c t i o n so fr e p r o d u c t i v et r a c t ,
neuroendocrine system, and immune system or by any
severe or exhausting general disease. The etiology of female
infertility in a diagnostic and treatment point of view is
summarized in Table 1 (based on the guidelines provided
by [1, 2] ) .T h er e p r o d u c t i v ea u t o i m m u n ef a i l u r es y n d r o m e
was originally described by Gleicher et al. in women with
endometriosis, infertility and increased autoantibodies [21].
Autoimmunemechanismsaswellasanincreasedproduction
of multiple autoantibodies are involved in such infertility
disorders as POF, endometriosis, polycystic ovary syndrome
(PCOS), unexplained infertility, and repeatedly unsuccessful
IVF attempts and may be responsible for the pathophysi-
ology of preeclampsia or spontaneous abortions, as stated
in many original articles as well as discussed in reviews
(Table 2)[ 19, 22–25]. Although not many studies have been
performed on humans, the role of cellular immunity in
ovarian autoimmunity, in addition to humoral immunity,
has been detected both locally in the ovary [26]a sw e l la si n
periphery [27]. However, due to the technical diﬃculties in
everyday laboratory work, most clinical studies are restricted
todetectingserumantibodiesinordertodeﬁneautoimmune
activation in a patient.
In Western Europe and North America, where tubal dis-
eases are relatively uncommon, endocrine dysfunctions can
be identiﬁed in about 10%–20% of women presenting with
infertility [28]. Most common cause for hypergonadotropic
hypogonadism is POF [1]. POF is deﬁned as secondary
amenorrhea with elevated gonadotrophin levels observed
under the age of 40 and aﬀect 1%-2% of women of the gen-
eral population [1]. POF is highly heterogeneous condition
and can be associated with autoimmune disorders, ovarian
surgery, iatrogenic causes such as chemoradiotherapy, sys-
temic diseases such as galactosaemia, or with genetic factors
[1]. In more than half of the cases, the development of POF
has been associated with autoimmune reactions to ovarian
tissue [29, 30]. An investigation of antiovarian autoimmune
reactions and autoantibodies may be severely hampered by
the fact that POF represents an end-stage of disease. By
the time when the disease in a women is diagnosed, she
has exhausted her follicular supply and, presumably, also
the target antigen for the autoimmune attack on her ovary.
Thus, the autoimmunity causal of POF can be diﬃcult to
detect retrospectively. Regardless of that, high prevalence of
antiovarianantibodies(AOA)(30%–67%)andothersorgan-
and nonorgan-speciﬁc autoantibodies have been observed in
patients with POF [29, 31, 32].
Normogonadotropic anovulation represents about 50%
of women with an endocrine cause of infertility and includes
mostly the patients with PCOS. PCOS aﬀects up to 4%–
10% of all women of reproductive age [33, 34]. PCOS is
characterizedbypolycystic ovaries, oligoanovulation, insulin
resistance, and hyperandrogenism or hyperandrogenaemia
[35,36].InfertilityinPCOSisassociatedwithanalterationinClinical and Developmental Immunology 3
Table 1: Etiology of female infertility (based on the diagnostic and
treatment guidelines provided by [1, 2]).
Anovulatory infertility
Hyperprolactinaemia
Pituitary adenoma
Hypogonadotrophic hypogonadism
Kallmann’s syndrome
Weight loss
Hypergonadotropic hypogonadism
Premature ovarian failure (POF) and early menopause
Gonadotrophin resistance due to a receptor defect
“Normogonadotropic” oligoanovulation
Polycystic ovary syndrome (PCOS)
Adrenal cause of hyperandrogenism
Genetic determinants
Turner syndrome, Swyer syndrome
Androgen insensitivity syndrome
Androgen synthesis disorders
Tuboperitoneal infertility
Tubal factor infertility
Endometriosis
Autoimmunity
POF
Recurrent pregnancy loss
Autoimmunity-associated infertility
Uterine abnormalities
Malformations
Submucous myomas
Endometrial adhesions
Unexplained infertility
folliculogenesis and in the selection of the dominant follicle
leadingtoanovulation[37].Anautoimmunemechanismhas
also been suggested in some cases of PCOS, where increased
prevalence of AOA and common organ- and nonorgan-
speciﬁc autoantibodies has been detected [19, 22, 25].
Tubal factor infertility accounts for 10%–30% in devel-
oped countries and up to 85% in developing countries of
reported cases of infertility [38]. Decreased fecundity may
be attributed to impaired ovum transport due to ﬁmbrial
damage and/or adnexal adhesions. The factors responsible
for tubal disease are diverse and include infections, pelvic
surgery, and endometriosis. Pelvic inﬂammatory disease
(PID) represents the link between STD and infertility. In
majority of cases, acute PID results from acute bacterial
endometritis and salpingitis. Most of the long-term con-
sequences of PID, however, stem from the destruction of
normal tubal structure, with or without tubal occlusion
[1]. While in developed countries, there has been a decline
in the incidence of STD salpingitis and correspondingly
in PID by the end of 1980s, a signiﬁcant rise of STD in
Eastern Europe and central Asia, has been documented
at the beginning of 1990s [2, 39, 40]. The incidence of
infertilityfollowingtheacutePIDdependsonvariousfactors
and varies from 6% to 60% [1]. In addition, there is
a silent, relatively asymptomatic PID, which could be the
case in up to 80% of chlamydial infections [41]. Genital
infection of Chlamydia trachomatis is currently the most
commonbacterialSTD(in20%–40%ofcases)anditcoexists
with the infection of Neisseria gonorrheae in 25%–50% of
cases [1]. Manifestation of tubal destruction, however, is
dependent also from the ability to activate autoimmune
inﬂammation. During chlamydial infection, similar to most
infections, the synthesis of heat shock proteins (HSPs) is
strongly upregulated. HSPs are the major antigens and can
induce a strong immune response [42]. Because there is a
strong amino acid sequence homology between microbial
and human HSPs, the induced immune response against
microbial HSPs may incite an autoimmune inﬂammatory
reaction in the host, culminating in tubal damage [42, 43].
Endometriosisischaracterizedbythegrowthofendome-
trialtissueoutsidetheuterinecavity.Itisacommondisorder,
aﬀecting 10%–20% of all women of reproductive age [44,
45]. The most frequent clinical presentations of endometrio-
sis include dysmenorrhea, pelvic pain, dyspareunia, infer-
tility, and pelvic mass. In addition to distorted pelvic
anatomy,alteredperitonealfunction,impairedimplantation,
and endocrine and ovulatory abnormalities, the alterations
in humoral and cell-mediated immune system reactions
contribute to the endometriosis-associated female infer-
tility [46]. Moreover, endometriosis has been labelled an
“autoimmune syndrome”. Classical autoimmune diseases, as
well as endometriosis, are characterized by polyclonal B-cell
activation and production of multiple diﬀerent autoantibod-
ies [21]. About 40%–60% of patients with endometriosis
have elevated autoantibody titers when tested against a
panel of autoantigens [47]. They often possess speciﬁc
antiendometrialantibodies[43,48,49],butalsoAOA,antin-
uclearautoantibodies(ANA),smoothmuscleautoantibodies
(SMA), and antiphospholipid antibodies (APA) [23, 50, 51].
Approximately 10%–20% of couples who are unable to
conceive are determined to have unexplained infertility [2].
Unexplainedinfertilityisatermappliedtoaninfertilecouple
whosestandardinvestigations(semenanalysis,tubalpatency,
andlaboratoryassessmentofovulation)yieldnormalresults.
A longer period has been suggested to be required for this
group of patients to achieve pregnancy without treatment,
as 70% of fertility rate is achieved in two years for the
group of unexplained infertility, whereas only nine months
are required for the fertile group to achieve the same rate
[52]. However, about 20%–30% of these patients remain
infertile even after 9 years of attempting to conceive [53].
Therefore, unexplained infertility appears to represent either
the lower extreme of normal distribution of fertility, or it
arises from a defect in fecundity that cannot be detected by
the routine infertility evaluation [2, 54–56]. Dysregulation
in immune system reactions with enhanced production of
autoantibodies is putative etiologic candidate for this group
of patients [32, 57, 58].
Thyroid autoantibodies have been associated with recur-
rent pregnancy loss, POF, and repeatedly unsuccessful IVF
attempts [11, 59, 60]. This is hypothetically explained
by the fact that organ-speciﬁc autoimmune diseases, like4 Clinical and Developmental Immunology
Table 2: Serum autoantibodies in female infertility and infertility-related diseases.
Patients (N) Autoantibodies Methods Study
design Authors (reference no.)
POF
POF (45)
AOA 47%∗
Antioocyte Aab 47%∗
AOA or anti-oocyte Aab 69%∗
Anti-LH 6.7% (also AOA positive)
AThA 18%∗
Antiplacental Aab 22%∗
ELISA CC Luborsky et al. 1990 [30]
POF (45) AOA 24–60%∗ ELISA CC Wheatcroft et al. 1994 [68]
POF (48) Anti-3 beta hydroxysteroid dehydrogenase
Aab 21%∗
IB, IF, cDNA
screening CC Arif et al. 1996 [69]
POF (46) AOA IgG, IgA or IgM 59%—IgG 74.1%, IgA
33.3%, IgM 29.6%∗ ELISA CC F´ enichel et al. 1997 [29]
(A) POF (14)
(B) IVF poor responders (29)
(C) IVF good responders (14)
FSH blocking IgG:
(A) 21.4%
(B) 6.9%
(C) 85%∗
IgG puriﬁcation,
cell culture
exposure
CC Reznik et al. 1998 [70]
POF (30)
Unexplained infertility (38)
AOA and AThA 60%∗
ANA and ACA 16%∗
AOA 53%∗
AThA 30%∗
EIA CC Luborsky et al. 1999 [32]
POS positive for AOA (36) Anti-FSH (anti-V14D) 94.4%∗ ELISA, IB, IF,
peptide screening P Gobert et al. 2001 [71]
POF (15)
AOA 66.6%∗
Antizona pellucida Aab 53.3%∗
TMA 33.3%
IHC CC Kelkar et al. 2005 [31]
IVF patients
IVF poor responders with male
infertility or TFI (26)
AOA 77%∗
Anti-FSH 92%∗
Anti-LH 65%∗ ELISA CC Meyer et al. 1990 [72]
IVF failure (80) AOA 12.5%∗ IF CC Geva et al. 1999 [62]
IVF failure (17)
1 out of 6 common Aab IgG 82.3%∗:
ACA 58.8%
LA 47.1%
AThA 58.8%
ANA 58.8%
SMA 11.8%
ELISA, IF, PDCA CC Putowski et al. 2004 [61]
IVF patients (135):
(A) PCOS, endometriosis,
unexplained infertility
(B) TFI or male infertility
(A) and (B) higher titer of anti-FSH IgG,
IgA and IgM∗ (A) 1 out of 7 common Aab
IgG 49%∗-ANA 2 preparations, SMA, PCA,
ACA, B2-GPI or anti-TPO
ELISA, IF CC Haller et al. 2007 [73]
I V Fp o o rr e s p o n d e r s( 1 6 ) Anti-FSH IgA 37.5%∗
Anti-FSH IgG 31.3%∗ ELISA CC Haller et al. 2008 [74]
TFI with IVF failure (156) AEA IgA∗ (antialpha enolase) IB, MS CC Sarapik et al. 2010 [43]
TFI (21) Antichlamydial HSP60 antibody titer∗ ELISA, IB, IF CC Rodgers et al. 2010 [42]
Non-IVF infertility patients
(A) Unexplained infertility (26)
(B) Unexplained abortion (24)
2 APA, 5 antihistone or 4 antipolynucleotide
IgG, IgA or IgM (A 88% and B 70.8%) ELISA P Gleicher et al. 1989 [66]
Pregnancy complications (69):
(A) Early pregnancy loss
(B) Foetal death
(C) Preeclampsia
AThA 37.7%∗:
(A) 37.9%∗
(B) 40.9%∗
(C) 33.3%∗
ELISA, PDCA, RIA CC Mecacci et al. 2000 [11]Clinical and Developmental Immunology 5
Table 2: Continued.
Patients (N) Autoantibodies Methods Study
design Authors (reference no.)
Infertility (108):
Menstrual cycle disturbances
Anovulation
Luteal phase deﬁciency
Unexplained infertility
PCOS
Endometriosis
1 out of 9 common Aab IgG 40.7%∗
ANA 13.9%∗
SMA 27.8%∗
TMA 1.9%∗
PCA 0.6%
B2-GPI 4.4%
ACA 5%
ELISA, IF CP Reimand et al. 2001 [25]
Infertility (438):
Endometriosis
TFI
Ovarian dysfunction
Male infertility
Unexplained infertility
Anti-TPO 14%:
18% in female infertility∗
29% in endometriosis∗
RIA CC Poppe and Velkeniers 2002
[60]
(A) Infertility (178)—PCOS,
endometriosis
(B) Uncomplicated pregnancy
(75)
(A) higher titer of anti-FSH (anti-V14D)
IgA∗
(B) lower titer of anti-FSH (anti-V14D) IgG,
IgM∗
ELISA CC Haller et al. 2005 [75]
Infertility-related diseases
Endometriosis (13) AOA, AEA, anti-theca cell Aab,
anti-granulosa cell Aab titers∗ IF, PHA CC Mathur et al. 1982 [50]
Endometriosis (59)
ANA 28.8%, LA 45.5% (inversely related to
disease stage)
1 out of 16 antigens IgG 64.5%
1 out of 16 antigens IgM 45.2%
IF, PDCA P Gleicher et al. 1987 [21]
Endometriosis (60) Anti-α 2HS glycoprotein and antitransferrin
titers∗ ELISA CC Mathur et al. 1999 [49]
PCOS (34) AOA IgG, IgA or IgM 44%—IgG 27%, IgA
3%, IgM 27%∗ ELISA CC F´ enichel et al. 1999 [19]
∗Statistically signiﬁcant compared to the reference (P<0.05), Aab-autoantibodies, ACA-anticardiolipin autoantibodies, AEA-antiendometrial autoantibod-
ies,ANA-antinuclearautoantibodies,AOA-antiovaryautoantibodies,APA-antiphospholipidautoantibodies,AThA-anti-thyroidautoantibodies,B2-GPI-anti-
beta 2-glycoprotein I autoantibodies, EIA-enzyme immunoassay, ELISA-enzyme-linked immunosorbent assay, FSH-follicle stimulating hormone, HSP-heat
shock protein, IF-immunoﬂuorescence, IB-immunoblot analysis, IHC-immunohistochemistry, IVF in vitro fertilization, LA-lupus anticoagulant, CC-case-
control study, CP-cases-population study, LH-luteinizing hormone, MS-mass spectrometry, P-prevalence, PCA-parietal cell autoantibodies, PCOS-polycystic
ovary syndrome, PDCA-phospholipid-dependent clotting assay, PHA-passive haemagglutination, POF-premature ovarian failure, RIA-radioimmune assay,
SMA-smoothmuscleautoantibodies,TFI-tubalfactorinfertility,TMA-thyroidmicrosomalautoantibodies,TPO-thyroidperoxidase,V14D-78-93aminoacid
immunodominant epitope on FSH.
thyroiditis, may develop secondary to some basic cellular
abnormalitythatdirectlyaﬀectspregnancyoutcome[60,61].
Repeated IVF failure has been associated with increased
prevalence of many autoantibodies, including AOA, APA,
ANA, SMA, and antisperm antibodies [61, 62]. Therefore,
the failure in diﬀerentiation of uterine T-cells into T-reg-
ulatory cells, as a key determinant of fertility in women has
been suggested to be a case in unexplained infertility [58].
Since the prevalence of AOA in unexplained infertility and
POF has been detected similar, the unexplained infertility
wassuggestedtorepresentanearlystageofautoimmunePOF
[32].
The impact of a particular autoantibody on the patho-
genesis of infertility is not uniformly understood. ANA
could interfere with early implantation of embryo and SMA
could alter the fallopian tube function [23]. It is concluded
that APA may be involved in uterine vascular modiﬁca-
tions aﬀecting implantation processes [63]. Except AOA in
ovulatory dysfunctions and disease-speciﬁc autoantibodies
described in case of endometriosis [43, 48, 49, 64], autoanti-
bodies detected in infertile patients are usually not speciﬁc
to infertility or to the gynaecological diseases leading to
infertility. Furthermore, the number of detectible autoan-
tibodies, in particular, has been proposed to predict the
pregnancy rate of IVF treatment [65]. Therefore, some
studies suggest lesser importance of speciﬁc autoantibodies
and stress the key role of overall activation of the immune
system in reduced fecundity [12, 65]. Consequently, the
autoimmune-associated infertility might be a polyclonal
event characterized by immunological defects at the T-cell
level which, similarly to classical autoimmune diseases, may
manifest itself in abnormal antibody production [66].
3.1. Antiovarian Autoantibodies. Although the presence of
AOA immunoglobulin G (IgG) has been documented in
diﬀerent groups of infertile patients (Table 2), there are no
epidemiological studies of ovarian autoimmunity. Using an
estimated prevalence of autoimmune POF, about 1.1 million6 Clinical and Developmental Immunology
women potentially have ovarian autoimmunity in US,
which makes ovarian autoimmunity far more common
than Addison’s disease, myasthenia gravis, or systemic lupus
erythematosus [67].
Some antibodies in the pool of AOA are suggested to
associate with a direct action on ovarian tissue, whereas
othershavenosucheﬀects,similartoautoantibodiesinother
autoimmune diseases [67]. Therefore, it is possible, that sev-
eral diﬀerent antigens are involved in ovarian autoimmunity,
asbothovariancellularandzonapellucida/oocyteantibodies
have been reported. Antioocyte antibodies were identiﬁed
already in 1966, and this was also one of the ﬁrst descriptions
of antiovarian autoimmunity [76]. High prevalence of
antizona pellucida antibodies have been detected in infertile
women, but also in healthy fertile women and even in men
[22]. Antibodies to steroid cells (SCA) are more prevalent in
POF patients with Addison’s disease (73%–87%), but rare in
those patients with other autoimmune disease (0%–8%) or
in0%–10% ofpatientswithisolatedPOF[22]. Steroidogenic
e n z y m e ss u c ha s1 7 α-hydroxylase, desmolase (P450-side
chain cleavage), 3β-hydroxysteroid dehydrogenase, and 21-
hydroxylase have been detected as the molecular targets of
SCA[69,77–80].Thealdehydedehydrogenaseandselenium-
binding protein 1 [81], human heat-shock protein 90-beta
[82] and antialpha-enolase [83] has recently been identiﬁed
as unique antigens in antiovarian autoimmunity associated
with POF and infertility. Gonadotrophin receptors have
been also investigated as a potential autoantibody targets.
While antibodies against LH receptor were ﬁrst identiﬁed
in 30% of IVF patients and in 50% of infertile patients
with endometriosis [68, 84], only few cases of POF patients
possessing antibodies to FSH receptor was documented [85].
A later study on FSH receptor blocking ability of these
antibodies has allowed questioning the pathophysiological
role of anti-FSH receptor antibodies in ovarian failure [70].
Although blocking antibodies are usually considered to
interact with receptors, the FSH and LH activity-inhibiting
antibodies could also directly recognize gonadotrophins
themselves. The presence of anti-FSH and anti-LH antibod-
ies in poor responder IVF patients has been associated with
immunizationagainstexogenousgonadotrophins[72].Until
recently, antigonadotrophin antibodies had been described
only in POF patients and that with conﬂicting results. By
using diﬀerent antibody assays, some authors suggest the
importance of only anti-LH antibodies [30], while others
evidence the association of POF with anti-FSH antibodies
[71].Thelattergrouppresentedantibodiesagainstβ-subunit
ofFSHinnearlyallofthestudiedAOA-positivePOFpatients
and no anti-LH activity was detected in these samples.
Moreover, these antibodies recognized epitopes all over the
β-subunit molecule, but a region between amino acids 78
and93(V14D)waspredominantly recognized inallsamples,
probably representing the immunodominant epitope [71].
The antibodies detected could readily explain the ovarian
failure in POF patients, since this part of the β-subunit
of FSH molecule is directly involved in determining the
speciﬁcity of receptor binding [86]. The ability of anti-FSH
to inhibit the function of FSH hormone has been detected
in men [87]. We have looked for the information regarding
to the presence of anti-FSH IgG, but also IgA and IgM,
in diﬀerent etiologic groups of female infertility, in healthy
women and during pregnancy. Pregnancy itself is accompa-
nied with a suppression of the development of new ovulating
follicles. This ovulatory quiescence is due to an inhibition
of the pituitary during pregnancy, as seen in the decreased
response of FSH and LH to GnRH administration [88]. In
addition, we have been interested in the etiologic factors
for overproducing anti-FSH antibodies of all subtypes in
infertile women as well as the putative pathological role of
these antibodies on folliculogenesis or on eﬀectiveness of
infertility treatment.
4. Follicle StimulatingHormone
4.1. Regulation of Gonadal Function by FSH. FSH is one of
the two pituitary gonadotrophins involved in the regulation
of the gonadal function. In females, FSH targets the receptor
expressedonlyongranulosacellsandinducesthematuration
of ovarian follicle [89]. FSH can inﬂuence the development
of preantral follicles via paracrine factors [90]. However,
growth of antral follicles becomes critically dependent on
FSH support, making a preovulatory follicle capable of
ovulation and forming a corpus luteum in response to the
mid-cyclesurgeofLH[91].TheroleofFSHanditssignalling
system is central in the normal reproductive function since
mutations in human FSH and its receptor are associated
with altered ovarian responses to the hormone, resulting in
various degrees of reduced reproductive function [92, 93].
4.2. Coding Genes and Molecular Structure of FSH. FSH is
a heterodimer, consisting of an α-subunit common to all
gonadotrophins (92 amino acids) and a unique β-subunit
(111 amino acids in FSH). Glycosylation of the gonadot-
rophins is important in circulatory persistence, clearance
and in bioactivity [94]. In a solvent environment, two FSH
molecules form an asymmetric unit in clasped hands-like
fashion [86]. The α-subunit carboxy-terminus as well as
carbohydrate residues linked to the α-subunit have been
implicated in receptor binding and activation [86, 94]. How-
ever, there is a cysteine noose, or determinant loop on the β-
subunit of FSH molecule (between amino acids 87 and 94),
theresidues ofwhich(Asp88, Asp90, andAsp93) play arole
in determining the speciﬁcity of FSH receptor binding [86].
The receptor-binding and hormone speciﬁcity determin-
ing β-subunit of FSH hormone is coded by FSHB gene at
the 11p13 [86]. Haplotype analysis has revealed two most
prevalent variants of FSHB gene—HAP1 and HAP13 [95].
These two core haplotypes have been suggested to be associ-
ated with female’s fecundity [95], but the association with
autoimmunity to FSH through gene expression in central
tolerance induction towards FSH had not been studied.
5.Anti-FSHAntibodiesBeing Primarily
NaturalAntibodies
We observed the physiological presence of antibodies
directed to FSH in a control group of healthy nonpregnantClinical and Developmental Immunology 7
women,signiﬁcantlylowervaluesofIgGandIgMbutnotIgA
anti-FSH antibodies during uncomplicated pregnancy [75],
and increased levels of these antibodies in infertile women
[73, 75]. A total of 233 consecutive women undergoing IVF
treatment in Estonia constructed the infertility patient group
inourstudies.Wehavedemonstratedtheproductionofanti-
FSH IgM antibodies associated with peripheral FSH hor-
mone levels. This association was detected among patients
with tubal and male factor infertility [73]. The production
of autoantibodies can be enhanced if there is elevated level
of autoantigen, as elevated FSH levels and AOA in case of
premature menopause [19]. Similarly, autoantibodies and
insulin levels in pancreatic β cells are correlated [18]. In
our study, the level of FSH remained between the reference
values for the majority of patients (peripheral level of FSH at
the early follicular phase of the menstrual cycle was 8.73 ±
4.69IU/L). Patients with anti-FSH IgM and FSH correlation
hadtheirs’hormonallevelratherlowerthaninotherpatients
and their infertility was not caused by immune system
dysregulation[73].Theseresultssuggestanti-FSHantibodies
being primarily the naturally occurring antibodies rather
than markers for autoimmunity against FSH hormone. This
hypothesis is further supported by the discussion provided
by Thomas [96] who concluded that physiological hormone
levels remain below a critical threshold for the stimulation
of relevant autoimmune reactions [96]. The reason for the
correlationbetweenanti-FSHIgMandthelevelofperipheral
hormone is still unknown but could be associated with
regulation of FSH bioactivity or with cyclic changes in ovary.
The ovulatory process has been compared to a classical local
inﬂammatoryreactionandleukocyteshavebeensuggestedto
participate actively in the cyclic events in the ovary [97–99].
Recently, cumulus and granulosa cells were shown to express
cellsurfacesignalingmoleculesknownaspatternrecognition
receptors acting as sensors of the external environment
important for the innate immune system to discriminate
self from nonself or altered self antigens [100]. Moreover, a
distinct group of mature B-lineage cells, termed B-1 cells are
believed to produce IgM natural antibodies, which interact
with variety of self determinants and may also cross-react
with bacterial antigens [101]. The natural IgMs represent
a primitive innate-like layer of adaptive immune system to
provide a primary line of defence against systemic infection
from viral and bacterial pathogens. There is also evidence
thatthenaturalantibodies maycontributetotheelimination
of autoantigens exposed during tissue damage, for instance,
[101].
In addition to the presence in female serum and in ovar-
ian tissue, FSH is also introduced to the genital tract mucosa
as a constituent of semen [102]. Female immune system
recognizes and reacts to the constituents of semen during
insemination, a phenomenon called seminal “priming”. Its
appropriate activation to induce sperm-prone mucosal toler-
ance facilitates subsequent pregnancy by sustaining “semial-
lograft” embryo development [103, 104]. During the process
of partner-speciﬁc tolerance, cell-mediated and humoral
immune reactions are initiated along with the production
of antibodies against semen-speciﬁc and shared maternal
antigens [103], such as FSH [102]. Therefore, the anti-FSH
IgA antibodies detected in the female circulation could be
alloantibodies initiated by semen. According to this hypoth-
esis, levels of anti-FSH IgA would be, depending on how
closely tolerance is induced, correlated with IgA antibodies
produced against sperm surface antigens. We studied the
correlations among patients with regard to their similarities
in immunotolerating conditions in the genital tract: (i) tubal
factor infertility group—women with tubal factor infertility
and normal semen quality observed in their partners, (ii)
male factor infertility group—healthy women and impaired
sperm quality observed in their partners, and (iii) combined
group of patients—women with endometriosis, PCOS or
unexplained infertility and normal semen quality observed
in their partners [74]. Among all subtypes of antibodies,
anti-FSH IgA and anti-sperm IgA were in correlation in
combined group of patients [74]. These results suggest that
both detected antibodies share the antigenic origin and
we propose anti-FSH IgA represent a natural activation of
female immune system in inducing the mucosal tolerance
to partner antigens. This idea is supported by the previous
study, where anti-FSH-β-chain antibodies were shown to be
absent in the sera of children [71].
Somewhat surprisingly, this correlation was only seen in
IVF patients with PCOS, endometriosis, and unexplained
infertility and not in patients with male factor or tubal
factor infertility [74]. The common feature for the former
threeinfertilitygroupsisdisturbedregulationoftheimmune
system [19, 24, 25, 57, 58]. Disruptions of the immune
system perturb the female’s immune response to semen
that is necessary for partner-speciﬁc tolerance and thereafter
elimination of activated clones to prevent autoimmunity
during pregnancy [103]. Semen exerts its “tolerance induc-
ing” eﬀect due to immunomodulating factors, most impor-
tantly transforming growth factor β1(TGFβ1)[ 105, 106].
Seminal levels of TGFβ1 correlate with sperm concentration
in ejaculate [105], the most decisive criterion for diagnosing
male infertility. However, there is some evidence that male
factor infertility is not associated with altered TGFβ1 levels
[107]. Although we did not distinguished subgroups of
patients with male infertility by sperm parameters, generally
theirlevelsofantispermandanti-FSHantibodies, orcorrela-
tions between the two, were similar to other patients. Unlike
other IVF patients participating in our study, patients with
infertility caused by tubal factor do not have disturbances in
female immune system regulation or seminal environment.
Thus, the diagnosis-restricted correlation of antisperm and
anti-FSH IgA cannot be easily explained. However, higher
levels of anti-FSH IgA showed an association with the
presence of the HLA-DQB1∗03 allele [73]. In this context, it
is interesting to refer to the published associations between
the HLA-DQB1∗03 allele, and the presence of the sperm-
immobilizing antibodies in cervical secretions [108]. Higher
production of antisperm antibodies has been detected in
patients with increased intestinal permeability in bowel
inﬂammatory disease, as a result of immunization against
intestinal microbes, which seems to share common anti-
genic epitopes with spermatozoa [109]. Consequently, the
elevated levels of anti-FSH IgA antibodies in IVF patients
could be explained by an upregulation of the normal8 Clinical and Developmental Immunology
mucosal immune response. Another possible explanation
of the increased anti-FSH IgA in IVF patients could be a
deﬁcits in producing antibodies that neutralize anti-FSH
immunoglobulins, which has been noted in patients who
produce antisperm antibodies [110]. These results together
suggest that the elevated values of anti-FSH IgA in IVF
patients could represent a failure in mucosal tolerance in the
genital tract, which could be genetically determined.
The production of anti-FSH IgG and IgM is decreased
during uncomplicated pregnancy [75]. This decrease cannot
be easily explained by the general view of a shift towards Th2
cytokines favouring humoral immunity during pregnancy
[111]. However, in fact, actual elevations of autoantibodies
have been detected in patients with pregnancy loss or recur-
rent abortion rather than in healthy noncomplicated preg-
nancy[111,112].Therefore,webelievethatthedevelopment
of the FSH-antibodies could reﬂect some other pregnancy-
associatedmechanismandthatanti-FSHantibodiescouldbe
the natural antibodies also in this occasion.
Figure 1(a) summarizes anti-FSH as natural antibodies
in healthy women. Humoral immune memory associated
with natural antibody-producing B-cells might contribute to
the homeostasis of the internal milieu. These cells are also
believed to be responsible for autoantigen-mediated clonal
selection in the process of initiating autoimmune reactions
[101].
6. IncreasedProduction of
Anti-FSHAntibodies Contributes to
Female Infertility
6.1. Higher Values of Anti-FSH in Infertile Women. We
observed that anti-FSH antibodies were predominantly
produced in infertile patients compared to healthy female
blood donors [73, 75]. As stated earlier, a group of infertile
patients from our studies were indicated for IVF, but
serum samples were obtained before the administration of
exogenous FSH [73]. Thirty-four percent of patients had
had at least one previous IVF procedure, but at least three
months had passed since the last FSH controlled ovarian
hyperstimulation (COH). Furthermore, using stratiﬁcation
by previous IVF procedures, anti-FSH antibody levels were
also increased in IVF patients who had never undergone
IVFproceduresbefore.Thefurtheranalysisdemonstratedno
signiﬁcant diﬀerences in anti-FSH antibody levels between
the combined groups of patients with tubal and male
factor infertility compared to the women with PCOS,
endometriosis, unexplained infertility, and female infertility
due to the other causes [73]. These data together suggest
that infertility itself, rather than the cause of infertility,
could be a predictive factor for the emergence of anti-FSH
antibodies, as previously concluded in case of AOA [113].
The intriguing question of what associates the production of
anti-FSH antibodies and female infertility stemmed directly
from this context.
Female infertility has been shown to be associated with
a higher occurrence of autoantibodies [17, 19, 23–25].
Except disease-speciﬁc autoantibodies described in case of
endometriosis and POF [22, 48, 49], autoantibodies detected
in infertile patients [17, 19, 23–25] are usually not speciﬁc
to infertility or to the gynaecological diseases leading to
infertility.Thus,ageneralimmunedysbalanceandactivation
of autoimmune processes are expected to be characteristic
for female infertility [12]. We have assessed a potential
susceptibility of a patient to autoimmunity by the presence
of at least 1 out of 7 common IgG type of autoantibodies in
relation to the autoimmunity-prone HLA-DQB1 alleles [73].
Anti-FSH IgM associated with the production of common
autoantibodies and this association was not confounded by
the presence of HLA-DQB1 alleles [73]. Our results along
the ones from the literature discussed above indicate that the
increased production of anti-FSH IgM could be related to a
general propensity to autoimmunity in infertile women.
The female infertility has often been studied in the con-
text of IVF. The follicular puncture performed in IVF, in
particular, can induce the production of AOA [17]. In
concordance with these data, we showed that the level
of anti-FSH IgM was higher in the patients who had
u n d e r g o n ep r e v i o u sI V Fp r o c e d u r e s[ 73]. The association
was revealed among IVF patients who were suﬀering from
PCOS, endometriosis, unexplained infertility, and infertility
due to the other causes but not among the women with
tubal or male factor infertility. These results encourage us
to speculate that repeatedly performed ovarian punctures
do not enhance antiovarian autoimmunity unless a patient’s
infertility is caused by the diseases associated with distur-
bances in immune regulation [17, 19, 23–25]. However,
simply based on the association study performed by us, we
cannot substantiate whether the antibodies themselves may
cause the need for multiple IVF procedures, or alternatively,
the use of IVF procedure per se may enhance the production
of anti-FSH.
The receptor-binding and hormone speciﬁcity deter-
mining β-subunit of FSH hormone is coded by FSHB
gene at the 11p13 [86]. Similarly to insulin gene poly-
morphisms aﬀecting central tolerance through the level of
gene expression in thymus [16], we were looking for an
association between the two FSHB core haplotypes [95]
and autoimmunity against FSH. As we could not detect
such relationship [73], we suggest that either these single
nucleotide polymorphisms do not aﬀect gene expression
in the thymus during central tolerance induction or that
FSHB-associated autoimmunity to FSH depends on HLA-
DQB1 allelic variants other than those evaluated in our study
[73].
The production of anti-FSH IgA is probably related to
diﬀerent factors than those involved in the production of
anti-FSH IgM [73]. Anti-FSH IgA were associated with the
presence of the HLA-DQB1∗03 allele [74] but not with the
cause of infertility, the history of previous IVF attempts
or the presence of other autoantibodies [73]. Therefore, it
would be tempting to speculate that anti-FSH IgA could not
be autoantibodies but alloantibodies triggered by seminal
FSH [102] and originating from mucosal response, as
discussed above. The reasons for an increased production
of this particular IgA isotype of antibodies in IVF patients,
however, remain unclear.Clinical and Developmental Immunology 9
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Figure 1:(a)Schematicoverviewofanti-FSHantibodiesinhealthyfemale.AntibodiesdetectedagainstFSHcouldbenaturalantibodiesalso
subjected to pregnancy-associated immune system regulations. Anti-FSH IgA detected in female circulation could be a part of the mucosal
responseinvolvedininducingimmunetolerancetoseminalconstituents.Anti-FSHIgMassociateswiththeperipherallevelofFSHhormone
and possibly contributes along with the mucosal-associated induction of IgA to the production of circulating anti-FSH IgG. (b) Increased
production of naturally occurring anti-FSH antibodies in case of female infertility. The production of anti-FSH IgM and IgG antibodies
could be related to a general propensity to autoimmunity or to previous IVF treatments. The elevated values of anti-FSH IgA could be
explained by a genetically determined failure in mucosal tolerance in the genital tract. Anti-FSH IgG and IgA antibodies, present in sera,
accumulate into the preovulatory follicle, where they aﬀect negatively oocyte maturation.
Correlation analysis of anti-FSH antibody values among
healthy controls showed that the levels of anti-FSH IgM
and IgA correlated both with the values of anti-FSH IgG
[73]. There is some indirect evidence that anti-FSH IgG
antibodies may, however, further worsen female fecundity
by reducing the FSH functionality [70, 72]. These data
lead us to investigate the eﬀect of anti-FSH antibodies on
folliculogenesis and developing infertility in women.10 Clinical and Developmental Immunology
6.2. Eﬀect of Serum Anti-FSH on Folliculogenesis. IVF has
become a promising treatment for various causes of infer-
tility. However, the success of attaining pregnancy following
IVF depends on the eﬀectiveness of COH. Serum levels of
anti-FSH IgG and IgA, but not IgM antibodies at the day
of oocyte retrieval, were in linear association with poorer
outcome of COH [114]. The outcome of COH was deﬁned
by the duration of FSH stimulation or the total FSH required
attaining an adequate response, the number of follicles
punctured or oocytes obtained after COH, the number of
matureoocytesorembryos,andtheamountofFSHrequired
per all of these parameters. The role of anti-FSH antibodies
revealed in our study was quite remarkable. For example,
our data suggest that a unit of diﬀerence in anti-FSH IgG
was associated with a 220.6IU increase in FSH needed for
one zygote, while the mean amount of FSH per zygote was
only 443.8 ± 401.2IU. Furthermore, the cutoﬀ value of >1.0
for anti-FSH IgA and IgG was calculated to be implicated to
poor ovarian response (≤3 oocytes) [114]. Series of dilutions
of mouse anti-human-FSH monoclonal IgG antibody were
used in ELISA test to create a concentration curve and
to predict serum anti-FSH IgG antibody concentration.
According to the curve, the levels of anti-FSH IgG > 1.0
was presumed to correspond to the antibody levels higher
than 0.5–0.6mg/L and could, therefore, represent 0.004%
of expected amount of total IgG (8–17g/L) in peripheral
blood. The same or even slightly lower levels of blocking and
stimulating serum TSH-receptor autoantibodies has been
demonstrated previously in patients with Graves’ disease
and in autoimmune hypothyroidism [115]. Since anti-FSH
antibodies are often detected in patients with AOA [71,
116] our results may simply reﬂect an impaired ovarian
function due to ovarian autoimmunity. The association
between antigonadotrophin [72]o rA O A[ 67] IgG in the sera
at oocyte retrieval and poor ovarian response to the FSH
stimulation has been shown previously.
Inadditiontoreﬂectingovarianautoimmunity,anti-FSH
antibodies may impair the function of exogenous or endoge-
nous FSH. For example, anti-FSH could form immune
complexes with FSH and induce its clearance, as recently
shown for creatine kinase in patients with corresponding
antibodies [117]. Also, anti-FSH could interrupt the binding
of FSH to its receptor. This hypothesis is supported by our
data suggesting anti-FSH antibodies in sera correlated with
antibodies directed against the 78–93 amino acid region of
the β-chain of the human FSH [71, 75], the domain that
determines FSH receptor binding speciﬁcity [86]. On the
otherhand, the study ofinvitro FSH-blocking ability of anti-
FSH IgG in women with good IVF response [70]s u g g e s t e d
that anti-FSH antibodies may be nonpathogenic. However,
this study did not specify which FSH epitopes were bound by
the pool of anti-FSH antibodies.
Althoughthe pathophysiology of anti-FSH in association
with poor ovarian response is still unclear, the importance of
these antibodies is noteworthy. Woman’s age and her ovarian
volume and the number of follicles counted at the early
follicular phase of her spontaneous menstrual cycle were sig-
niﬁcant clinical parameters predicting the outcome of COH
[114], as also demonstrated by others [118]. Yet, anti-FSH
antibodies could represent an additional importance to the
clinical parameters like age, follicle number, or ovarian
volume in predicting the outcome of COH. Furthermore, if
the inﬂuence of anti-FSH on the ovarian response is revealed
in the IVF patients (where supraphysiological amounts of
FSH were administered to stimulate folliculogenesis), the
importanceofthoseantibodiesinunstimulatedspontaneous
folliculogenesis might be substantial.
6.3. Changes in Serum Levels of Anti-FSH during COH in
Relation to Follicular Fluid. Serum levels of anti-FSH IgG
and IgA, but not IgM antibodies, decreased following COH,
conducted with GnRH antagonist protocol [114]. Although
interpretation of these results is not straightforward, we
believe the decrease in anti-FSH antibody levels could partly
be explained by the supraphysiological levels of immuno-
suppressive progesterone and testosterone [114, 119, 120]
produced in COH. This hypothesis is supported by our
previousdatasuggestinganoveralldecreaseinthenumberof
commonIgGautoantibodiesduringCOH[57].Additionally,
anti-FSH antibodies could form immune complexes with
administered recombinant FSH or with endogenous FSH
(produced in pituitary prior to administration of GnRH
antagonists), resulting in the decrease in antibody levels.
However, the levels of anti-FSH IgM remain unchanged
after COH [114]. As IgM antibodies also form immune
complexes, the reactivation of the immune system towards
novel epitopes on the FSH molecule and the production
of anti-FSH IgM during COH might be speculated. As
well, immunization against exogenous gonadotrophins has
also been previously suggested [72]. This hypothesis is
further supported by our ﬁndings and that found from
the literature that an increase in IgM type of anti-FSH
[73]a n dA O A[ 17, 32, 73, 121] associated with repeated
IVF procedures. However, it was also reported that AOA
were initiated by ovarian puncture rather than administered
FSH [17]. Additionally, circulating anti-FSH could pass into
the follicular ﬂuid during follicle maturation; however, this
decrease would hardly be detectable in sera by current
laboratory tests.
The charge- and size-selective ovarian blood-follicle
barrier is open for IgG to pass into the follicular ﬂuid [122]
and the concentration of total IgG and IgA in follicular ﬂuid
as well as in blood should be equivalent [123]. We have
measured the presence of anti-FSH IgG, IgA and IgM in
negligible amounts in follicular ﬂuid [114]. The level of anti-
FSH IgA also correlated with the level of same antibody in
peripheral blood [114]. However, anti-FSH IgG seemed to
accumulate into the growing follicle, since the concentration
of follicular anti-FSH IgG associated positively with the
diameter of a follicle, reﬂecting the maturity of a follicle
[114]. The increase in follicular anti-FSH IgG with the
growth of the follicle is not a simple reﬂection of anti-FSH
IgG serum levels, as serum anti-FSH IgG levels signiﬁcantly
decreased during COH [114]. Logically, follicular anti-FSH
IgG levels correlated with the amounts of recombinant FSH
used for COH and FSH levels measured in the follicle [114].
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[124, 125], and expectedly, follicular FSH correlates with
the amount of FSH administered exogenously [67, 114].
Thus, anti-FSH IgG could diﬀuse along with the antigen
to the follicular ﬂuid during the COH. Although anti-
FSH IgA and IgM were detected in the follicle, levels of
these antibodies were not associated with follicle diameter
[114], which is in agreement with other authors [126]. In
addition, anti-FSH IgM levels in the follicle were very low
compared to serum antibody levels [114], in concordance
with that reported by Clarke and coworkers [123], where
total IgM in the follicle represented approximately 10% of
its plasma concentration [123]. Figure 1(b) summarizes our
studies on anti-FSH antibodies in cases of female infertility.
These results emphasize the need for further research to
elucidate the clinical relevance of anti-FSH antibodies in the
spontaneous menstrual cycles.
Finally, low-dose prednisolone therapy has improved
pregnancy rate in patients with recurrent IVF failure [62,
67, 127] and in non-IVF patients [128]. Diﬀerent treatment
regimes of oral prednisolone has been suggested, such
as 10mg/d during one month prior to the COH [62],
0.5mg/kg/d starting from the beginning of COH until the
end of 1st trimester of pregnancy, and followed by lowering
the dose thereafter [127], or 10mg/d in the 1st week, 5mg/d
in the 2nd week, 2.5mg/d in the 3rd week, and 2.5mg/d 3
times a week during the last (4th) week before intrauterine
insemination [128]. However, considering the time duration
of ovarian folliculogenesis, the treatment should start at least
1-2 months before COH [67]. Most beneﬁt of immunosup-
pressive treatment can gain infertile patients who represent
antiovarian autoimmunity [129]. Testing serum anti-FSH
antibodies could help infertility treatment specialists to
identify those patients.
7. Conclusions
Female fertility can be aﬀected by diseases or dysfunctions
of reproductive tract, neuroendocrine system, and immune
system. Reproductive autoimmune failure can be associated
with overall activation of immune system or with immune
system reactions speciﬁcally directed against ovarian anti-
gens. Antiovarian autoantibodies are mostly directed against
β-subunit of follicle stimulating hormone (anti-FSH). Anti-
FSH could be natural antibodies. Anti-FSH IgA detected in
female circulation could be a part of the mucosal response
involved in inducing immunotolerance to seminal con-
stituents. Anti-FSH IgM associates with the peripheral level
of FSH hormone and contributes along with the mucosal-
associated induction of IgA to the production of circulating
anti-FSH IgG. Additionally, higher production of anti-FSH
antibodiescouldcontributetofemaleinfertility.Theinduced
production of anti-FSH IgM antibodies could be related
to a general propensity to autoimmunity or to previous
IVF treatments. The elevated values of anti-FSH IgA could
indicate genetically determined failure in mucosal tolerance
in the genital tract. Serum IgG and IgA anti-FSH antibodies,
measured at the day of oocyte retrieval, predict the outcome
of ovarian stimulation, additionally to that observed with
age and other clinical parameters characterizing the ovarian
reserve. A population of anti-FSH antibodies which are pro-
duced against 78–93 epitope on the β-chain might modulate
therecognitionandbindingofFSHtoitsreceptorandmight,
therefore, have a pathological inﬂuence on ovarian function.
We have also demonstrated that anti-FSH IgG, IgA, and
traces of IgM antibodies were detectable in the follicular
ﬂuid and that anti-FSH IgG antibodies accumulated into the
preovulatory follicle. Immunosuppressive treatment could
improve the pregnancy rate in anti-FSH seropositive infertile
patients.
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